New shot slashes hidden heart risk in phase 2 trial

NCT ID NCT04270760

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested olpasiran, an injectable drug, in 281 adults with high lipoprotein(a) – a genetic risk factor for heart disease. Participants received either olpasiran or a placebo. The main goal was to see how much the drug lowered Lp(a) levels after 36 weeks. Results showed a significant reduction, suggesting olpasiran may help control this stubborn risk factor.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olpasiran (AMG 890)
What this could lead to: If successful, olpasiran could become a new treatment to lower high lipoprotein(a), a genetic risk factor for heart disease and stroke.
What could go wrong: This is a phase 2 trial with 281 participants, so results are still early. It is not yet proven to reduce heart attacks or strokes, only to lower a lab marker.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease cardiovascular disorder Dyslipidemias hyperlipidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASE

Contacts and locations

Locations

Aarhus Universitetshospital

Aarhus N, 8200, Denmark
Academisch Medisch Centrum

Amsterdam, 1105 AZ, Netherlands
Asahi General Hospital

Asahi-shi, Chiba, 289-2511, Japan
Asahikawa City Hospital

Asahikawa-shi, Hokkaido, 070-8610, Japan
Baylor College of Medicine

Houston, Texas, 77030, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Clinique des Maladies Lipidiques de Quebec Incorporated

Québec, Quebec, G1V 4W2, Canada
Columbia University Medical Center

New York, New York, 10032, United States
Core Research Group Pty Ltd

Milton, Queensland, 4064, Australia
Crossroads Clinical Research Inc

Mooresville, North Carolina, 28117, United States
Dr Heart Pty Ltd

Woolloongabba, 4102, Australia
Ecogene-21

Chicoutimi, Quebec, G7H 7K9, Canada
Excel Medical Clinical Trials

Boca Raton, Florida, 33434, United States
Haga Ziekenhuis

The Hague, 2545 AA, Netherlands
Herlev Gentofte Hospital

Herlev, 2730, Denmark
Johns Hopkins

Baltimore, Maryland, 21287, United States
Kanazawa Medical University Hospital

Kahoku-gun, Ishikawa-ken, 920-0293, Japan
LMC Clinical Research Incorporated

Brampton, Ontario, L6S 0C6, Canada
LMC Clinical Research Incorporated Thornhill

Concord, Ontario, L4K 4M2, Canada
Linear Clinical Research Limited

Nedlands, Western Australia, 6009, Australia
Monash Medical Centre

Clayton, Victoria, 3168, Australia
Mount Sinai Hospital

New York, New York, 10029, United States
New York University

New York, New York, 10016, United States
Piedmont Healthcare

Atlanta, Georgia, 30309, United States
Protenium Clinical Research

Hurst, Texas, 76054, United States
Regionshospitalet Viborg

Viborg, 8800, Denmark
Research Institute of McGill University Health Center - Glen Site

Montreal, Quebec, H4A 3J1, Canada
Rijnstate Ziekenhuis

Arnhem, 6815 AD, Netherlands
Royal Prince Alfred Hospital

Camperdown, New South Wales, 2050, Australia
Saitama Medical University Hospital

Iruma-gun, Saitama, 350-0495, Japan
The Jikei University Kashiwa Hospital

Kashiwa-shi, Chiba, 277-8567, Japan
Thjonustumidstod Rannsoknaverkefna

Kopavogur, 201, Iceland
Universitair Medisch Centrum Utrecht

Utrecht, 3584 CX, Netherlands
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States
VieCuri Medisch Centrum

Venlo, 5912 BL, Netherlands
Westside Medical Associates of Los Angeles

Beverly Hills, California, 90211, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.